Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
Lists
Only you see this
Abstract
Taken together, these findings support the clinical investigation of selective CDK7 inhibition combined with ET to overcome treatment resistance in ER+ breast cancer. In addition, our study highlights the potential of increased c-Myc activity and intact p53 as predictors of sensitivity to CDK7i-based treatments.
BibTeX
@inproceedings{guarducci2024selective,
author = {Cristina Guarducci and Agostina Nardone and Douglas Russo and Zsuzsanna Nagy and Capucine Héraud and Albert Grinshpun and Qi Zhang and Allegra Freelander and Matthew Leventhal and Avery Feit and Gabriella Cohen and Ariel Feiglin and Weihan Liu and Francisco Hermida‐Prado and Nikolas Kesten and Wen Ma and Carmine De Angelis and Antonio Morlando and Madison O'Donnell and Sergey Naumenko and Shixia Huang and Quang‐Dé Nguyen and Ying Huang and Luca Malorni and Johann S. Bergholz and Jean J. Zhao and Ernest Fraenkel and Elgene Lim and Rachel Schiff and Geoffrey I. Shapiro and Rinath Jeselsohn},
title = {{Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer}},
booktitle = {Clinical},
year = {2024},
doi = {10.1158/1078-0432.ccr-23-2975},
}Loading related content...